153
194.
Legally J., Lemeshow S., Soulnier F. A new Simplified Acute
Physiology Score (SAPS II) based on a European//North American multicenter study
// JAMA, 1993, v.270, p. 136-142.
195.
Lethauser B., Matthias F.R., Nicolai U., Voss R. Hemostatic
abnormalitiesand the severity of illness in patients at the onset of cilinically defined
sepsis. Possible indication of the degree of endothelial cell activation // Intensive
Care Med., 1996, v.22., p.631-636
196.
Levi M., de Jonge E., van der Poll T. Advances in the understanding of
the pathogenetic pathways of disseminated intravascular coagulation result in more
insight in the clinical picture and better management strategies // Semin. Thromb.
Hemost., 2001, v.27, p. 569 -575.
197.
Levi M. Current understanding of disseminated intravascular coagulation
// Br. J. Haematol., 2004, v.124, p. 567-576.
198.
Levi M. Disseminated intravascular coagulation: What's new? // Crit.
Care Clin., 2005, v.21, p. 449-467.
199.
Levine R.L., Garland D., Oliver C.N. et al. Determination of carbonyl
content in oxidatively modified proteins // Methods Enzymol., 1990, v.186, p. 464-
478.
200.
Lijnen H.R., Collen D. Mechanism of physiological fibrinolysis //
Baillieres. Clin. Haematol., 1995, v.8, p. 277-290.
201.
Lipinski B., Worowski K. Detection of soluble fibrin monomer
complexes in blood by means of protamin sulphate test // Thromb. Diath. Haemorr.,
1968, v.20, p. 44-49.
202.
Loisa P., Rinne T., Laine S. Et al. Anti-inflammatory cytokine response
and development of multiple organ failure in severe sepsis // Acta Anaesthesiol.
Scand., 2003, v.47, p. 319-325.
203.
Lowry O.H., Rosebrough N.J., Farr A.L. et al. Protein measurement with
Folin phenol agent // J. Biol. Chem., 1951, v.193, p. 265-275.
154
204.
Lowry S.F., Awad S., Ford H. et al. Static and dynamic assessment of
biomarkers in surgical patients with severe sepsis // Surg. Infect (Larchmt), 2004, v.
5, p. 261-268.
205.
Maeda K., Hirota M., Ichihara A. et al. Applicability of disseminated
intravascular coagulation parameters in the assessment of the severity of acute
pancreatitis // Pancreas, 2006, v.32, p. 87-92.
206.
Mammen E.F. Perspectives for the future // Intensive. Care Med., 1993,
v.19, p. S29-S34.
207.
Marcel M. Levi, Alvin H Schmaier // Disseminated Intravascular
Coagulation. Medscape cam, 2009.
208.
Mari D., Mannucci P.M., Coppola R. et al. Hypercoagulability in
centenarias: the paradox of successful aging // Blood., 1995, v.85, p. 3144-3149.
209.
Marik P.E. Total splanchnic resuscitation, SIRS, and MODS // Crit.
Care. Med., 1999, v.27, p. 257-258.
210.
Mavrommatis A.C., Theodoridis T., Orfanidou A. et al. Coagulation
system and platelets are fully activated in uncomplicated sepsis // Crit. Care Med.,
2000, v.28, p. 451-457.
211.
McCoy C-, Matthews S.J. Drotrecogin alfa (recombinant human
activated protein C) for the treatment of severe sepsis // Clinical Therapeutics., 2003,
v.25, p. 396-421.
212.
McGill S.N., Ahmed N.A., Christon N.V. Increased plasma von
Willebrand factor in the systemic inflammatory response syndrome is derived from
generalized endothelial cell activation // Crit. Care Med., 1998, v.26, p. 296-300.
213.
Merli G.J. Low-molecular-weight heparins versus unfractionated heparin
in the treatment of deep vein thrombosis and pulmonary embolism // Am. J. Phys.
Med. Rehabil., 2000, v.79, p. S9-S16.
214.
Merlini P.A., Ardissino D. Current status of activation markers in
ischemic heart disease: markers of coagulation activation // Thromb. Haemostas.,
1997, v.78, p. 276-279.
155
215.
Mihara M, Uchiyama M. Determination of malonaldehyde precursor in
tissues by thiobarbituric acid test // Anal. Biochem., 1978, v.86, p. 271-280.
216.
Mombelli G., Im Hof V., Haeberli A. et al. Effect of heparin on plasma
fibrinopeptide A in patients with acute myocardial infarction // Circulation., 1984,
v.69, p. 684-689.
217.
Mombelli G., Monotti R., Haeberli A., Straub P.W. Relationship
between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC
and various non-tromboembolic diseases // Thrombos. Haemostas., 1987, v.58, p.
758-763.
218.
Mordente A., Miggiano G.A., Martorana G.E. et al. Alkaline
phosphatase inactivation by mixed function oxidation systems // Arch. Biochem.
Biophys., 1987, v.258, p. 176-185.
219.
Mosesson M.W. Fibrinogen and fibrin structure and functions // J.
Thromb. Haemost., 2005, v.3, p. 1894-1904.
220.
Motoyama T., Okamoto K., Kukita I. Et al. (2003) Possible role of
increased oxidant stress in multiple organ failure afte systemic inflammatory
response syndrome // Crit. Care Med., 2003, v.31, p. 1048-1052.
221.
Murray J.F., Matthay M.A., Luce J.M., Flick M.R. An expanded
definition of the adult respiratory distress syndrome // Am. Rev. Respir. Dis., 1988,
v.38, p. 720-723.
222.
Nachman R.L., Silverstein R. Hypercoagulable states // Ann. Intern.
Med., 1993, v.119, p. 819-827.
223.
Neuhof H., Lasch H.C. Interaction between intravascular coagulation
and tissue perfusion // Clin. Hemorheol., 1984, v.4, p. 5-13.
224.
Neuhof H., Seeger W. Intermediur und abbauprodukte der gerinnung als
mediateren pulmonaler gefaibreaktionen // Hamostaseologie., 1985, v.5, p. 116-120.
225.
Nosel H.L., Yudelman I., Canfield R.E. et al. Measurement of
fibrinopeptide A in human blood // J. Clin. Invest., 1974, v.54, p. 43-53.
226.
Al-Nozha M., Gader A. M., Al -Momen A. K. et al. Haemostatic
variables in patients with unstable angina // Int. J. Cardiol, 1994, v.43, p. 269-277.
156
227.
Okabayashi K., Wada H., Ohta S. et al. Hemostatic markers and the
sepsis-related organ failure assessment score in patients with disseminated
intravascular coagulation in an intensive care unit // Am. J. Hematol., 2004, v.76, p.
225-229.
228.
Okajima K., Koga S., Okabe H., İnoue M., Takatsuki K. et al.
Characterization of the fibrinolytic state by measuring stable cross-linked fibrin
degradation products in disseminated intravascular coagulation associated with acute
promyelocytic leukemia // Acta Haematol. (Basel), 1989, v.81, p. 15-18.
229.
Ott P., Astrup L., Hartving J.R. et al. Assessment of D-dimer in plasma:
diagnostic value in suspected deep venous thrombosis of the leg // Acta Med. Scand.,
1988, v.224, p. 263-267.
230.
Poll T., de Jonge E., Levi M. Regulatory role of cytokines in
disseminated intravascular coagulation // Semin. Throm. Hemost., 2001, v.27, p. 639-
651.
231.
Powell J.J., Fearon K.C.H., Siriwardena A.K. he modern concepts of
physiopathology and treatment severe pancreatitis // Brit. J. of Intensive Care.,2000,
v.10, №2, p. 51-59
232.
Prieto M. Disseminated intravasscular coagulation // Interational
Congress Series, 2002, v.1237, p. 163-168.
233.
R.B., Rapaport S.Y. The partical thromboplastin time with kaolin a
simple screening method for first stage plasma clotting factors deficiencies // Am. J.
Physiol., 1961, v.36, p. 212-219.
234.
Pruitt J.H., Copeland E.M., Moldawer L.L. Interleukin-1 and interleukin-
1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock
// Shock., 1995, v.3, p. 235-251.
235.
Quick A.J. On the constitution of prothrombin // Am. J. Physiol., 1943,
v.140, p. 212-220.
236.
Radenkovic D., Bajec D., Karamarkovic A. et al. Disorders of
hemostasis during the surgical management of severe necrotizing pancreatitis //
Pancreas., 2004, v.29, p. 152-156.
157
237.
Ranson J.H. Diagnostic standards for acute pancreatitis // World J.
Surgery, 1997, v.21, р. 136-142.
238.
Riddell D.R., Owen J.S. Nitric oxide and platelet aggregation // Vitam.
Horm., 1999, v.57, p. 25-48.
239.
Ridker P.M. Fibrinolytic and inflammatory markers for arterial
occlusion: the evolving epidemiology of thrombosis and hemostasis // Thromb.
Haemostas., 1997, v.78, p. 53-59.
240.
Rickles F. R., Edwards R. L. Activation of blood coagulation in cancer:
Trousseau`s syndrome revisited // Blood., 1983, v.62, p. 14-31.
241.
Risch L., Monn A., Luthy R. et al. The predictive characteristics of D-
dimer testing in outpatients with suspected venous thromboembolism: a Bayesian
approach // Clin. Chim. Acta, 2004, v.345, p. 79-87.
242.
Rocha E., Paramo J.A., Montes R., Panizo C. Acute generalized,
widespread bleeding. Diagnosis and management // Haematologica., 1998, v.83, p.
1024-1037.
243.
Rowlands B.J., Soong C.V., Gardiner K.R. The gastrointestinal tract as
barrier in sepsis //Br. Med. Bull., 1999, v.55, p. 196-211.
244.
Townsend C. M., Beauchamp R.D., Everes B.M., Mattox K.L. Sabistom
textbook of surgery. Philadelphia, PA: WB Saunders 17th ed. 2004
245.
Sakaguchi S. Metabolic aspects of endotoxin as a model of shock-
approached from oxidative stress // Yakugaku Zasshi, 2004, v.124, p. 69-87.
246.
Saldeen T. Clotting, microembolism, and inhibition of fibrinolysis in
adult respiratory distress // Surg. Clin. North Am., 1983, v.63, p. 285-304.
247.
Salvemini D., Botting R. Modulation of platelet function by free radicals
and free-radicals scavengers // Trends. Pharmacol. Sci., 1993, v.14, p. 36-42.
248.
Salvemini D., Cuzzocrea S. Oxidative stress in septic shock and
disseminated intravascular coagulation // Free. Rad.Biol. Med., 2002, v.33, p. 1173-
1185.
249.
Saxena R., Gupta P.K., Ahmed R. et al. D-dimer test: diagnostic role in
clinical and sub-clinical DIC // Indian J. Pathol. Microbiol., 2003, v.46, p. 425-426.
158
250.
Scheraga H.A. The thrombin-fibrinogen interaction // Biophysical
chemistry., 2004, v.112, p. 117-130.
251.
Brunicardi F.C., D.K.Anderson., T.R. Bilar., D.L.Dunn., J.G.Hunter.,
R.E.Pollock . Schwartz’s Principles of surgery 17-th ed. 2006. p.1937
252.
Shacter E., Williams J.A., Lim M., Levine R.L. Differential
susceptibility of plasma proteins to oxidative modification: examination by westerm
blot immunoassay // Free Radic. Biol. Med., 1994, v.17, p. 429-437.
253.
Shacter E., Williams J.A., Levine R.L. Oxidative modification of
fibrinogen inhibits thrombin-catalyzed clot formation // Free Radic. Biol. Med., 1995,
v.18, p. 815-821.
254.
Shitrit D., Izbicki G., ShitritA.B. et al. Prognostic value of a new
quantitative D-dimer test in critically ill patients 24 and 48 h following admission to
the intensive care unit // Blood Coagul. Fibrinolysis., 2004, v.15, p. 15-19.
255.
Shorr A.F., Trotta R.F., Alkins S.A. et al. D-dimer assay predicts
mortality in critically ill patients without disseminated intravascular coagulation or
venous thromoembolic disease // Int. Care Med., 1999, v.25, p. 207-210.
256.
Short M.A. linking the sepsis triad of inflammation, coagulation and
suppressed fibrinolysis to infants // Advances Neon. Care., 2004, v.4, p. 258-273.
257.
Sobel M., Sternbergh W.C., Marques D., Grimsdale A.S. A comparative
study of heparin responses in arterial and venous thromboembolism using molecular
markers for thrombosis // Circulation, 1993, v.88, p. 426-431.
258.
Soria J., Soria C., Ryckewaert J. J. A solid phase imunoenzymological
assay for the measurement of human fibrinopeptide A // Thromb. Res., 1980, v.20, p.
425-435.
259.
Sok D.E. Oxidative inactivation of brain alkaline phosphatase
responsible for hydrolysis of phosphocholine // J. Neurochem., 1999, v.72, p. 355-
362.
260.
Strieker H., Marchetti O., Haeberli A., Mombelli G. Hemostatic
activation under anticoagulant treatment: a comparison of unfractionated heparin
159
vs. Nadroparin in the treatment of proximal deep vein thrombosis // Thromb.
Haemost., 1999, v. 82, p. 1227-1231.
261.
Sultanov H.A., Rahimov V.S., Ömarov T.İ. Diagnostics of disorders of
hemostatc system based on D-dimer and Fibrinopeptid-A dynamics during acute
destructive pancreatitis / Abstracts of XII international euroasian congress of surgery
and gastroenterology, 2011, p. 192
262.
Taira K., Matsunaga T., Kawahara S., et al. Fragments of urinary
fibrib/frinogen degradation products and cross-linked fibrin degradation products in
various diseases //Thromb. Res., 1989, v.53, p. 367-377.
263.
Takakaski H., Urano T., Takada Y. et al. Fibrinolytic parameters as an
admission prognostic marker of head injury in patients who talk and deteriorate // J.
Neurosurg., 1997, v.86, p. 768-772.
264.
Taylor A.E., Martin D., Parker J.C. The effects of oxygen radicals on
pulmonary edema formation // Surgery., 1983, v.94, p. 433-438.
265.
Taylor F.B. J., Kinasewitz G.T . The diagnosis and management of
disseminated intravascular coagulation // Curr. Hematol., 2002, v.1, p. 34-40.
266.
Tripodi A., Mannucci P.M Markers of activated coagulation and their
usefulness in cilinical laboratory // Clin. Chem., 1996, v.42, p. 664-669.
267.
Uchida K., hasui Y., Osawa T. Covalent attachment of 4- hydroxyl – 2
– nonenal to erythrocyte proteins // J. Biochem. (Tokyo), 1997, v.122, p. 1246-1251.
268.
Van Deventer S.J., Buller H.R., ten Cate J.W., et al. Experimental
endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic
and complement pathway // Blood.,2006,v.76, p. 2520-2526.
269.
Vincent J.L., de Mendonce A., Cantraine F. et al. Use of the SOFA
score to assess the incidence of organ dysfunction / failure in intensive care
units: results of a multicenter prospective study. Working group on “sepsis –
related problems” of the European Sociaty of Intensive Care Medicine // Crit. Care
Med., 1998, v.26, p. 1793 - 1800.
160
270.
Wada H., Sakuragawa N., Mori Y. et al. Hemostatic molecular markers
before the onset of disseminated intravascular coagulation // Am. J. Hematol., 1999,
v.60, p. 273-278.
271.
Wada H. disseminated intravascular coagulation // Clin. Chim.
Acta.,2004, v.344, p. 13-21.
272.
Warkentin T.E. An overview of the heparin-induced thrombocytopenia
syndrome // Semin. Thromb. Hemost., 2004, v.30, p. 273-283.
273.
Van Wersch J. W. J., Tjwa M. K. T. Coagulation / fibrinolysis balance
and lung cancer // Haemostasis., 1991, v. 21, p. 117-123.
274.
Wilde J.T., Kitchen S., Kinsey S. et al. Plasma D-dimer levels and their
relationship to serum fibrinogen/fibrin degradation products in hypercoagulable states
// Br. J. Haematol., 1989, v.71, p. 65-70.
275.
Williams M., Simms H.H. Prognostic usefulness of scoring systems in
critically ill patients with severe acute pancreatitis // Crit.Care.Med., 1999, v.27, p.
901-907.
276.
Winterbourn C.C., Buss L.H., Chan T.P. et al. Protein carbonyl
measurements show evidence of early oxidative stress in critically ill patients // Crit.
Care Med., 2000, v.28, p. 143-149.
277.
Wort S.J., Evans T.W. The role of endothelium in modulating vascular
control in sepsis and related conditions // Br. Med Bull., 1999, v.55, p. 30-48.
278.
Yang H., Sheng Z., Guo Z. et al. Oxygen free radical injury and its
relation to bacterial and endotoxin translocation after delayed fluid resuscitation:
clinical and experimental study // Chin. Med. J. (Engl.), 1997, v.110, p. 118-124.
279.
Yu M., Nardella A., Pechet L. Screening tests of disseminated
intravascular coagulation: guidelines for rapid and specific laboratory diagnosis //
Crit. Care Med., 2000, v.28, p. 1777-1780.
280.
Zwart L.L., Meerman J.H., Commandeur J.N., Vermeulen N.P.
Biomarkers of free radical damage applications in experimental animals and in
humans // Free Radic. Biol. Med., 1999, v.26, p.202-226.
161
281.
Poeze M, Ramsay G, Gerlach H, Rubulotta F, Levy M: An international
sepsis survey: a study of doctors’ knowledge and perception about sepsis// Critical
Care, 2004, v. 8, p.409-413.
282.
Martin J Wildman, David A Harrison, Anthony R Brady, Kathy
RowanCase mix and outcomes for admissions to UK adult, general critical care units
with chronic obstructive pulmonary disease: a secondary analysis of the ICNARC
Case Mix Programme Database . // CriticalCare 2005, 9(Suppl 3):S38-S48 (17 June
2005).
283.
Kakkar AJ, Kadziola Z, Williamson RCN et al. Low molecular weight
heparin therapy and survival in advanced cancer // Blood., 2002, v. 100, p. 148a.
284.
Carey M.J., Rodgers G.M. Disseminated intravascular coagulation:
Clinical and laboratory aspects // Am. J. Hematol., 1998, v.59, p. 65-73.
285.
Gattani AM, Mandeli J, Bruckner HW. Tumor markers in patients with
pancreatic carcinoma // Cancer, 1998, v.78, p. 57-62.
Dostları ilə paylaş: |